Sessions

Working With a CDMO is not Just an Outsourcing Contract but a Partnership: Learnings from Successful Biotech/CDMO Partnerships
Workforce of the Future: Talent, Change Management and Enabling Future Development
Delivering Projects and Managing Timelines in the Variable, Continuously Changing Environment Of Cell and Gene Therapy
How to Market my Biotech to Investors: Lessons Learned from Successful Investment and Funding Rounds
Patient and Payer Challenges: Enabling Access to Patients through Market Access, Pricing and Patient-Led Discussion
Moving the Industry Towards Automated Systems for Scale-up Success
Tech Review: New Platforms and Closed-Systems to Enable Commercial Success
Overcoming Challenges and Setting Up for Success on the Path to Commercialisation
Overcoming Challenges and Setting Up for Success on the Path to Commercialisation

Working With a CDMO is not Just an Outsourcing Contract but a Partnership: Learnings from Successful Biotech/CDMO Partnerships

27 Jan 2022
11:00
SPONSORED BY
CTI
BioCentriq
BioBridge Global
Porton Advanced

11:00 Chairperson’s Opening
Timothy J. Schroeder, Chairman and Chief Executive Officer, CTI

11:05 Highlight the Growth of the Cell and Gene Industry, the Demand for Manufacturing and Necessitating the Need for Partnerships in Today’s Environment

Timothy J. Schroeder, Chairman and Chief Executive Officer, CTI

11:20 The 4 Keys to Successful CDMO Partnerships in CGT

  • Capacity and core capabilities are table stakes
  • Common goals, specialization, collaboration, and transparency are critical

Alex Klarer, Director of Cell Therapy, Biocentriq

11:35 Growing in the CDMO Space: Customer Acquisition or Partnership Journey?

  • Beginning the Customer Journey with the end in mind — Transactional vs collaborative relationships
  • Delivering Integrated services in an emerging market—needs and challenges
  • The importance of Creative problem solving in addressing evolving scientific and supply chain challenges
  • Establishing transparent and complementary relationships to enable a manufacturer to become an extension of the developer’s team

Becky Cap, Senior Vice President, BioBridge Global and Chief Operating Officer, GenCure
&
Michael Titus, Vice President of Quality and Operations, Avobis Bio

11:50 How CDMO’s Can Assist Biotechnology Companies Developing Gene and Cell Therapies
Qian Hao, Chief Technology Officer, Porton Advanced

12:05 Panel Discussion & Speaker Q&A

 

Speakers

Timothy Schroeder
Chairman, Chief Executive Officer and Founder
CTI
Alex Klarer
Director of Cell Therapy
BioCentriq
Becky Cap
Chief Operating Officer, GenCure, Senior Vice President
BioBridge Global
Michael Titus
Vice President of Quality and Operations
AVOBIS BIO
Qian Hao
Chief Technology Officer
Porton Advanced